This report by Lower Drug Prices Now highlights how drug corporations’ spending on lobbying and elections match up with Senator Susan Collins’ votes on health care and prescription drug pricing. Connecting the Dots on Pharma Lobbying, Political Donations and Senator Collins’ Votes on Drug Pricing and Access, shows that while Senator Collins claims to be independent from the Trump Administration and the drug industry, her votes tell a different story.
Our research details drug corporations’ spending on lobby expenditures and political contributions in order to influence policy outcomes that preserve Big Pharma’s high profits and monopoly power over prices. Since her election to the Senate in 1996, Senator Collins has received over $478,000 from drug industry corporations, PACS and individuals.
